Palatin Technologies Inc (PTN): R&D Expense
$14.90M
Year ended 2025-06-30
$12.33M
Trailing 12 months to 2026-03-31
-11.3%
3-year compound annual growth
+1.3%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-06-30 | $14.90M | -33.5% | 2025-09-23, From 2024-07-01 |
| 2024-06-30 | $22.40M | -1.0% | 2025-09-23, From 2023-07-01 |
| 2023-06-30 | $22.63M | +6.1% | 2024-09-30, From 2022-07-01 |
| 2022-06-30 | $21.33M | +65.0% | 2023-09-28, From 2021-07-01 |
| 2021-06-30 | $12.93M | -7.4% | 2022-09-22, From 2020-07-01 |
| 2020-06-30 | $13.96M | -6.0% | 2021-09-28, From 2019-07-01 |
| 2019-06-30 | $14.86M | -54.4% | 2020-09-25, From 2018-07-01 |
| 2018-06-30 | $32.57M | n/c | 2019-09-12, From 2017-07-01 |
| 2017-06-30 | $32.57M | n/c | 2020-09-25, From 2016-07-01 |
| 2016-06-30 | $43.07M | +75.4% | 2018-09-13, From 2015-07-01 |
| 2015-06-30 | $24.56M | +126.8% | 2017-09-25, From 2014-07-01 |
| 2014-06-30 | $10.83M | +2.8% | 2016-09-19, From 2013-07-01 |
| 2013-06-30 | $10.53M | -23.8% | 2015-09-18, From 2012-07-01 |
| 2012-06-30 | $13.81M | +33.1% | 2014-09-12, From 2011-07-01 |
| 2011-06-30 | $10.38M | -15.6% | 2013-09-27, From 2010-07-01 |
| 2010-06-30 | $12.29M | n/a | 2012-09-10, From 2009-07-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Palatin Technologies Inc (PTN) | 2025-06-30 | $14.90M | -33.5% |
| Abbott Laboratories (ABT) | 2025-12-31 | $2.94B | +3.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $9.95B | -10.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $13.34B | +21.3% |
| Pfizer Inc (PFE) | 2025-12-31 | $10.44B | -3.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $14.66B | -14.9% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $1.90M | +11.8% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $15.79B | -12.0% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $1.90M | -7.5% |
Compare PTN, ABT, BMY, LLY side by side · Screen every company in Pharmaceutical Preparations ↗